Prof G Markets: Novo Nordisk Tanks 30%, P&G Takes a Tariff Hit & SoFi’s Monster Second Quarter
Release Date: July 30, 2025
Hosts: Scott Galloway and Ed Elson
Network: Vox Media Podcast Network
Introduction
In this episode of Prof G Markets, hosts Scott Galloway and Ed Elson delve into significant movements within the capital markets, focusing on three major stories: the sharp decline of Novo Nordisk’s stock, Procter & Gamble’s (P&G) substantial tariff impacts, and SoFi’s impressive second-quarter performance. This detailed analysis provides listeners with insightful perspectives on how these developments shape the financial landscape.
Novo Nordisk’s Stock Plummet: A Deep Dive into the Decline
Ed Elson opens the discussion by highlighting the dramatic 30% drop in Novo Nordisk’s shares following the company’s second consecutive outlook reduction. The revised forecast now anticipates full-year revenue growth between 8% and 14%, a significant decrease from the initial 21% projection. Similarly, profit growth expectations have been trimmed to 10-16%, down from a previously projected 24%.
“So, disappointing numbers from Novo Nordisk. And the market is understandably punishing them for it. The stock is now down nearly 40% year to date.” [02:30]
Factors Behind the Decline
The primary reason cited by Novo Nordisk’s management is the emergence of copycat GLP-1 drugs. Companies like HIMSS began offering compounded GLP-1s during a supply shortage, which supposedly eroded Novo Nordisk’s market share.
However, producers Claire and analysts Emily Field and Nick Modi provide a more nuanced perspective. They point out two critical issues:
-
End of GLP-1 Supply Shortage: The initial issue of supply constraints allowing competitors to produce compounded GLP-1s is no longer relevant.
-
Competitive Pressure from Eli Lilly: Novo Nordisk’s main competitor, Eli Lilly, has overtaken them in the U.S. market with its product Zepbound, now holding a 60% market share. Despite this, Novo Nordisk failed to address the competitive threat during their investor call.
“Well, the market's reaction today is telling you that they're not taking perhaps drastic enough action to address this volume problem that they have.” [08:03]
Emily Field suggests that Novo Nordisk's focus on smaller competitors like HIMSS, rather than acknowledging Eli Lilly’s dominance, has led to investor dissatisfaction.
Market Reaction and Future Outlook
Ed Elson summarizes the sentiment:
“So the takeaway is pretty clear here. Eli Lilly is crushing it. Zepbound is on a tear... Novo Nordisk continues to get hammered.” [08:58]
Despite the bleak outlook, there remains a glimmer of potential opportunity as GLP-1s are still expanding, with a significant portion of Americans interested but not yet utilizing them. However, without addressing the core competitive challenges, Novo Nordisk’s trajectory remains uncertain.
Procter & Gamble’s Earnings: Navigating Tariff Pressures
Transitioning to Procter & Gamble (P&G), Ed Elson discusses the company’s recent earnings report, which, while slightly exceeding expectations with revenues of $21 billion (a 2% increase), revealed concerning tariff impacts.
“The real headline came in the company's outlook for 2026, which revealed that the company would incur $1 billion in costs due to tariffs.” [13:30]
Detailed Analysis of Tariff Impact
The CEO of P&G stated:
“Tariffs alone are a 5-point headwind to core EPS growth in fiscal 2026. We will look for every opportunity to mitigate these impacts, including sourcing flexibility, productivity improvements, and pricing with innovation.” [14:15]
The CFO provided further clarity, mentioning a mid-single-digit percentage increase in prices for about a quarter of P&G’s products, affecting everyday items like laundry detergent and toothpaste.
Expert Insights
Nick Modi and Dan Dolev from RBC Capital Markets analyze the broader implications:
“We all have to kind of anticipate over the next several quarters, is as companies get more clarity, they're going to start responding, and that's where we're going to start seeing some more pricing in the market.” [16:47]
Emily Field notes that P&G’s decision to pass costs onto consumers by raising prices is reflective of textbook economic responses to tariffs, confirming widespread expert predictions.
“This is very simple economics that is now playing out in the real world...” [18:07]
Conclusion on P&G’s Strategy
Ed Elson underscores the inevitability of shared burdens between shareholders and consumers when tariffs lead to increased costs. P&G’s approach aligns with economic theories, distributing the financial impact without causing unsustainable price hikes.
SoFi’s Stellar Second Quarter: Riding the Wave of Digital Banking
Shifting focus to SoFi, Ed Elson highlights the company’s exceptional second-quarter performance, marked by a 44% increase in net revenues, a 34% surge in user growth, and a 72% rise in fee-based revenues. The stock experienced a significant uplift, soaring by as much as 15% in a single day.
“SoFi crushed expectations with its second-quarter earnings... the market is going crazy for it.” [19:30]
Growth Drivers and Strategic Positioning
Analysts Claire and Sam provide in-depth insights into SoFi’s growth trajectory:
“This was an inflection quarter in our view... the lending platform is something to watch out.” [21:11]
Sam elaborates on SoFi’s competitive edge over traditional and digital banks alike, citing its diverse product offerings, strong brand presence, and innovative lending platform allowing for extensive growth beyond conventional banking restrictions.
“They're kind of a marketplace for loans right now.” [22:12]
Demographic Advantages and Future Potential
Ed Elson emphasizes the demographic tailwind propelling SoFi, particularly among younger generations who prefer digital-only banking solutions.
“SoFi is the leading digital bank... Only 20% of Americans have digital-only bank accounts today, but that number's been growing rapidly.” [24:21]
This trend, coupled with SoFi’s strategic investments and higher interest offerings, positions the company favorably to capitalize on the expanding digital banking market.
“If you're betting on financial services, you should be betting on digital.” [24:40]
Final Insights and Takeaways
Ed Elson wraps up the episode by reinforcing the significance of digital transformation in financial services and the practical application of economic principles in corporate strategies.
“This is very simple economics that is now playing out in the Real world...” [18:07]
The discussions on Novo Nordisk, P&G, and SoFi collectively underscore the dynamic interplay between market forces, competitive strategies, and macroeconomic factors shaping the capital markets.
Conclusion
This episode of Prof G Markets provides a comprehensive analysis of critical market movements affecting major corporations. From the challenges faced by Novo Nordisk amidst competitive pressures, P&G’s navigation through tariff-induced costs, to SoFi’s robust growth in the digital banking sphere, listeners gain a nuanced understanding of the factors driving these companies' performances. The inclusion of expert opinions and notable quotes enriches the discussion, making it an invaluable resource for anyone looking to deepen their financial literacy and market insights.
For more insights and detailed market analyses, subscribe to Prof G Markets on your favorite podcast platform or contact the team at markets@profgmedia.com.